申请人:Hoffmann-La Roche Inc.
公开号:US05990105A1
公开(公告)日:1999-11-23
The present invention relates to novel compounds of the general formula ##STR1## wherein R.sup.1 is hydrogen; R.sup.2 is hydrogen, trifluoromethyl or lower alkyl; R.sup.3 is hydrogen or amino; or R.sup.1 and R.sup.2 or R.sup.3 and R.sup.2 taken together are --CH.dbd.CH--CH.dbd.CH--; Z is pyrimidin-4-yl, pyridin-4-yl, pyridin-2-yl or phenyl; R.sup.4, R.sup.5 are each independently hydrogen, lower alkyl, trifluoromethyl, halogen, lower alkoxy, nitrilo, amino, lower alkyl-amino, di-lower alkyl-amino, piperazinyl, morpholinyl, pyrrolidinyl, vinyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 cycloalkenyl, t-buthylethinyl, hydroxyalkylethinyl, phenylethinyl, naphthyl, thiophenyl, or phenyl, which may be substituted by halogen, lower alkoxy, lower alkyl, trifluoromethyl or nitro, or a group --NH(CH.sub.2).sub.n NR.sup.6 R.sup.7, --N(CH.sub.3)(CH.sub.2).sub.n NR.sup.6 R.sup.7, --NH(CH.sub.2).sub.n -morpholin-4-yl or --NH(CH.sub.2).sub.n OH; n is 2-4 R.sup.6 and R.sup.7 are each independently hydrogen or lower alkyl, and to their pharmaceutically acceptable salts. It has been found that the compounds of formula I possess a selective affinity to 5HT-6 receptors.
本发明涉及一般式为##STR1##的新化合物,其中R.sup.1为氢;R.sup.2为氢,三氟甲基或较低的烷基;R.sup.3为氢或氨基;或者R.sup.1和R.sup.2或R.sup.3和R.sup.2一起取--CH.dbd.CH--CH.dbd.CH--;Z为嘧啶-4-基,吡啶-4-基,吡啶-2-基或苯基;R.sup.4,R.sup.5各自独立地为氢,较低烷基,三氟甲基,卤素,较低烷氧基,氰基,氨基,较低烷基氨基,二较低烷基氨基,哌嗪基,吗啉基,吡咯烷基,乙烯基,C.sub.3 -C.sub.6环烷基,C.sub.3 -C.sub.6环烯基,叔丁基乙炔基,羟基烯基,苯基乙炔基,萘基,噻吩基或苯基,可以被卤素,较低烷氧基,较低烷基,三氟甲基或硝基取代,或者为--NH(CH.sub.2).sub.n NR.sup.6 R.sup.7,--N(CH.sub.3)(CH.sub.2).sub.n NR.sup.6 R.sup.7,--NH(CH.sub.2).sub.n -吗啉-4-基或--NH(CH.sub.2).sub.n OH的基团;n为2-4,R.sup.6和R.sup.7各自独立地为氢或较低烷基,以及它们的药用可接受盐。已发现,式I的化合物具有对5HT-6受体的选择性亲和力。